Clover Health Shares Rise on New Coverage Initiation

Clover Health shares are trading higher following a new Buy initiation from Deutsche Bank, with the stock gapping up to nearly $4.70 on elevated volume. While analysts remain divided on the valuation, recent data highlights significant insider selling by top executives despite the positive technical momentum.
GN stocks/nasdaq reports that CLOV gapped up to open at $4.48 before trading as high as $4.695, with volume reaching 1.47 million shares. The article also notes recent insider sales by CEO Andrew Toy and VP Joseph Frank Oldakowski, both executed under 10b5-1 plans to cover tax obligations.
Source: GN stocks/nasdaqClover Health stock climbed 8.5% following a Buy rating from Deutsche Bank, which highlighted the firm's Medicare Advantage growth potential and proprietary technology platform.
Source: GN stocks/nasdaq






